Skip to Main Content

There is, according to Wall Street, no worse investment in biotech than Galapagos NV.

The Belgian company trades at an enterprise value approaching negative $2 billion. That means its liquid assets, mostly cash, are worth more than the company itself. It means, according to the market, that every dollar Galapagos puts toward inventing new drugs would be better spent doing pretty much anything else.


“Basically the company is being valued as though they are lighting that cash on fire,” said Emily Field, an equities analyst at Barclays in London.

Get unlimited access to award-winning journalism and exclusive events.


Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!

To submit a correction request, please visit our Contact Us page.